Related Experiment Video
Updated: May 9, 2026
Utilizing High Resolution Ultrasound to Monitor Tumor Onset and Growth in Genetically Engineered Pancreatic Cancer Models
Published on: April 7, 2018
Utilizing endoscopic ultrasound-guided fine needle aspiration in identifying molecular targets for pancreatic cancer
Onyekachi Henry Ogbonna1, Muhammad Wasif Saif
1Tufts University School of Medicine. Boston, MA 02111, USA.
Abstract:
Pancreatic cancer remains a devastating disease, with poor survival rates and high recurrence rates with current treatment regimens. Over the years we have come to understand the complex biology of this cancer, involving cross-talking signaling pathways that proffers resistance to current therapy. Several molecularly targeted agents remain in development. At the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, an abstract (#4051) was presented which explored using endoscopic ultrasound-guided fine needle aspiration of pancreatic cancer tissue to identify molecular targets, and argued for the feasibility of personalizing pancreatic cancer therapy based on the activated molecular pathways identified. We summarize their findings and discuss the possibility of utilizing this model to obtain a better understanding of pancreatic cancer at each stage of its metamorphosis and target therapy at these different levels.
Insights
Personalizing pancreatic cancer therapy is feasible. Endoscopic ultrasound-guided fine needle aspiration can identify molecular targets for tailored pancreatic cancer treatment, improving outcomes for this devastating disease.
Area of Science:
- Oncology
- Gastroenterology
- Molecular Biology
Background:
- Pancreatic cancer presents significant challenges due to poor survival and high recurrence rates with existing treatments.
- The complex biology of pancreatic cancer involves interconnected signaling pathways contributing to therapeutic resistance.
- Targeted therapies are under development to address these complex mechanisms.
Purpose of the Study:
- To evaluate the feasibility of using endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) for molecular profiling of pancreatic cancer.
- To explore the potential for personalizing pancreatic cancer therapy based on identified molecular targets and activated pathways.
- To discuss the utility of this approach in understanding pancreatic cancer progression and guiding targeted interventions.
Main Methods:
- Review and summarization of findings presented at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract #4051).
- Utilizing endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) to obtain pancreatic cancer tissue for molecular analysis.
- Identifying activated molecular pathways within the tumor tissue.
Main Results:
- Demonstrated the feasibility of EUS-FNA for molecular target identification in pancreatic cancer.
- Highlighted the potential for tailoring treatment strategies based on individual tumor molecular profiles.
- Showcased a model for understanding pancreatic cancer at different stages of its development.
Conclusions:
- Personalized therapy for pancreatic cancer is achievable through molecular profiling of tumor tissue obtained via EUS-FNA.
- This approach offers a pathway to better understand pancreatic cancer biology and optimize targeted treatment strategies.
- Further research utilizing this model could lead to improved therapeutic outcomes for pancreatic cancer patients.
